In recent years, several novel therapeutic classes for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), including antibody-drug conjugates, CAR T, and most recently, bispecific T-cell engaging antibodies, have emerged. During this activity, a panel of clinical experts will present the latest data on these therapeutic advances. They will also discuss the integration of these treatments in clinical practice while a patient with R/R DLBCL shares key aspects of their therapeutic journey.
Upon completion of this activity, participants should be better able to:
Director, Lymphoma Immunotherapy Program
Tisch Cancer Institute at Mount Sinai
Faculty, Icahn Genomics Institute
Icahn School of Medicine at Mount Sinai
Hess Center for Science and Medicine
Mount Sinai Hospital
New York, NY
Assistant Attending, Lymphoma Service and Cellular Therapy Service
Memorial Sloan-Kettering Cancer Center
Assistant Professor, Medicine
Weill Cornell Medical College
New York, NY
Director, Indolent Lymphoma and Chronic Lymphocytic Leukemia
John Theurer Cancer Center
Associate Professor, Hackensack Meridian School of Medicine
Hackensack, NJ
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Joshua Brody, MD, has no relevant financial relationship(s) with ineligible companies to disclose.
Lorenzo Falchi, MD, has relevant financial relationships with AbbVie, Evolveimmune, Genmab, Roche/Genentech (Consultant); AbbVie, ADC Therapeutics, AstraZeneca, Genentech, Ispen, Seagen (Advisory Board); AbbVie, Genmab, Innate Pharma, Roche/Genentech (Grant/Research Support).
Lori A. Leslie, MD, has relevant financial relationships with AbbVie, ADC Therapeutics, AstraZeneca, Eli Lilly, Epizyme, Genmab, Janssen, Kite Pharma, Merck, Pharmacyclics, Seattle Genetics, TG Therapeutics (Consultant); AbbVie, AstraZeneca, BeiGene, Eli Lilly, Epizyme, Genmab, Janssen, Kite Pharma/Gilead, Pharmacyclics, Seattle Genetics, TG Therapeutics (Speaker/Speaker’s Bureau); Epizyme, TG Therapeutics (Advisor).
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – JA-4008290-0000-24-001-H01-P)
Type of Activity: Knowledge
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hour(s).
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected].
Users must:
There is no fee to participate.
In order to claim MOC points, users must:
MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.
For Pharmacists: You must provide your NABP eProfile ID and date of birth (MM/DD format) in order to receive credit for the activity.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
